Skip to content

Study · Case report or series · n = 28 · 1995

1 result

Administration of a gonadotropin-releasing hormone agonist during pregnancy: follow-up of 28 pregnancies exposed to triptoreline.

Elefant E, Biour B, Blumberg-Tick J, Roux C, Thomas F

Fertility and sterility1 May 1995Cited by 20 (Europe PMC)

PMID7720926 (opens in a new tab)DOI10.1016/s0015-0282(16)57557-8 (opens in a new tab)PepBankPUB-07720926
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanCase report or seriesSafety outcome

    In pregnancies inadvertently exposed to triptoreline, no teratogenic or fetal toxic effect was noted.

    In plain wordsIn pregnancies inadvertently exposed to triptoreline, no birth-defect or toxic effect on the fetus was noted.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    Direction not reportedTeratogenic or fetal toxic effects
    Study

    n = 28

    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    No teratogenic or fetal toxic effect has been noted.
    3 context sentences
    Title · context
    Administration of a gonadotropin-releasing hormone agonist during pregnancy: follow-up of 28 pregnancies exposed to triptoreline.
    Summary · context
    Prospective follow-up of exposed pregnancies and case reports.
    Summary · context
    Inadvertent pregnant women receiving a treatment, mainly for endometriosis or IVF.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase 4NCT04797338

Gonadotropin Releasing Hormone Agonist (GnRHa) Versus Estrogen and Progesterone for Luteal Support in High Responders

Assaf-Harofeh Medical Centern = 10029 Dec 2017 to est. 30 Sept 2021

Pregnancy Early · Miscarriage · Ovarian Hyperstimulation Syndrome

Trial pageClinicalTrials.govUpdated 1 Apr 2021

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.